Jefferies analyst, Gena Wang, reiterated her Buy rating on shares of Progenics Pharmaceuticals (NASDAQ: PGNX) and raised her price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE